Trials / Completed
CompletedNCT01208831
An East Asian Study of LDE225
An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LDE225 |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2010-09-24
- Last updated
- 2020-12-19
Locations
4 sites across 3 countries: Hong Kong, Japan, Taiwan
Source: ClinicalTrials.gov record NCT01208831. Inclusion in this directory is not an endorsement.